Literature DB >> 10209187

Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England.

M P Lunn1, H Manji, P P Choudhary, R A Hughes, P K Thomas.   

Abstract

Although there are now widely accepted diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) there are few epidemiological data. A prevalence study was performed in the four Thames health regions, population 14 049 850. The prevalence date was 1 January 1995. Data were from a national consultant neurologist surveillance programme and the personal case series of two investigators. A diagnosis of CIDP was made according to definite, probable, possible, or suggestive diagnostic criteria. A wide difference in prevalence rates between the four health regions was noted, probably due to reporting bias. In the South East Thames Region, from which the data were most comprehensive the prevalence for definite and probable cases was 1.00/100 000; the highest total prevalence (if possible and suggestive cases were included) would have been 1.24/100 000. On the prevalence date 13% of patients required aid to walk and 54% were still receiving treatment.

Entities:  

Mesh:

Year:  1999        PMID: 10209187      PMCID: PMC1736351          DOI: 10.1136/jnnp.66.5.677

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  47 in total

Review 1.  Chronic inflammatory demyelinative polyneuropathy.

Authors:  Gérard Said
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

Review 2.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

4.  Restless leg syndrome in different types of demyelinating neuropathies: a single-center pilot study.

Authors:  Marco Luigetti; Alessandra Del Grande; Elisa Testani; Giulia Bisogni; Anna Losurdo; Nadia Mariagrazia Giannantoni; Salvatore Mazza; Mario Sabatelli; Giacomo Della Marca
Journal:  J Clin Sleep Med       Date:  2013-09-15       Impact factor: 4.062

5.  Incidence and prevalence of CIDP and the association of diabetes mellitus.

Authors:  R S Laughlin; P J Dyck; L J Melton; C Leibson; J Ransom; P J B Dyck
Journal:  Neurology       Date:  2009-07-07       Impact factor: 9.910

Review 6.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 7.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

8.  Intravenous immunoglobulin as an intervention strategy of risk factor modification for prevention of severe infection in heart transplantation.

Authors:  E Sarmiento; M Arraya; M Jaramillo; P Diez; J Fernandez-Yañez; J Palomo; J Navarro; J Carbone
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

9.  Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.

Authors:  Carlo Lazzaro; Leonardo Lopiano; Dario Cocito
Journal:  Neurol Sci       Date:  2014-01-28       Impact factor: 3.307

10.  Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada.

Authors:  Gord Blackhouse; Kathryn Gaebel; Feng Xie; Kaitryn Campbell; Nazila Assasi; Jean-Eric Tarride; Daria O'Reilly; Colin Chalk; Mitchell Levine; Ron Goeree
Journal:  Cost Eff Resour Alloc       Date:  2010-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.